Skip to main content
رجوع
Watch Compare

Corbus Pharmaceuticals Holdings, Inc.

جودة البيانات: 83%
CRBP
NASDAQ Manufacturing Chemicals
KWD 10.14
▲ KWD 0.14 (1.40%)
6 months return
—
Momentum
Neutral
ROE
-77.32%

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-77.32%
أقل من متوسط القطاع (-54.47%)
ROIC-66.01%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio6.31
Interest CoverageN/A

التقييم

PE (TTM|NTM)
-2.32 | -2.04
أقل من متوسط القطاع (-1.50)
P/B Ratio1.97
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -64.50 M

Price History

الاتجاهات المالية

السعر المستهدف للمحللين

9 محللين
Buy
+300.0%
upside to target
الحالي
KWD 10.14
Consensus Target
KWD 40.56
KWD 28.00
أدنى
KWD 57.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-2.04
ربحية السهم المستقبلية
-KWD 4.90
الإيرادات المقدّرة
2.70 M

مفاجآت الأرباح

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -KWD 1.22 · Rev Est: 0.0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -KWD 1.39 -KWD 1.44 -KWD 1.90 -KWD 1.25 — —
Estimate -KWD 1.07 -KWD 1.33 -KWD 1.71 -KWD 1.58 -KWD 1.22 -KWD 1.24
المفاجأة -29.56% -8.36% -11.31% +20.69% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -77.32% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -78.54 M
ROE -77.32% ROA -66.95%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -64.50 M
ROIC -66.01% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 6.31
Debt / Equity N/A Current Ratio 6.31
Interest Coverage N/A Asset Turnover N/A
Working Capital 90.51 M Tangible Book Value 92.15 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -2.32 · EV/EBITDA: N/A
P/E Ratio -2.32 Forward P/E -2.04
P/B Ratio 1.97 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 67.37 Fwd Earnings Yield N/A
FCF Yield -35.46%
Market Cap 181.89 M Enterprise Value 154.90 M

Per Share

EPS: -5.90 · FCF/Share: -3.64
EPS (Diluted TTM) -5.90 Revenue / Share N/A
FCF / Share -3.64 OCF / Share -3.64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 82.12% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 82.12%
SBC-Adj. FCF -71.60 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — 0.0 881,705.0
Net Income -78.54 M -40.21 M -44.60 M -42.35 M -45.64 M
EPS (Diluted) -5.90 -3.68 -10.31 -10.15 —
Gross Profit — — — — —
Operating Income -85.31 M -48.72 M -45.08 M -39.84 M -55.99 M
EBITDA — — — — —
R&D Expenses 70.10 M 32.22 M 31.17 M 16.14 M 36.45 M
SG&A Expenses — — — — —
D&A 233,000.0 588,000.0 640,601.0 762,995.0 999,817.0
Interest Expense 0.0 1.80 M 3.81 M 3.10 M 2.71 M
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 168.20 M 155.88 M 28.27 M 66.31 M 107.73 M
Total Liabilities 20.69 M 13.45 M 35.18 M 33.32 M 38.62 M
Shareholders' Equity 147.50 M 142.43 M -6.90 M 32.99 M 69.11 M
Total Debt — — 17.89 M 21.59 M 21.19 M
Cash & Equivalents 28.49 M 17.20 M 13.72 M 17.00 M 25.01 M
Current Assets 166.95 M 152.98 M 23.55 M 60.18 M 100.20 M
Current Liabilities 20.69 M 11.82 M 31.89 M 12.64 M 17.01 M

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1605 نظير)
المقياس السهم وسيط القطاع
P/E -2.3 -1.5
P/B 2.0 1.6
ROE % -77.3 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock
VYSVX VYSVX
0.03% weight
GSSC logo GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF
0.01% weight